Physician profile
Peter Sohn
NPI 1225579675
$5,220.63
in general payments reported to CMS, 2019-2025
21 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.39 · 2021: $289 · 2022: $418 · 2023: $2,191 · 2024: $1,450 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,486.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,541.06 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $484.31 | 2023-2025 | Veltassa, Korsuva |
| Amgen INC. | $406.82 | 2023-2025 | Tavneos, Parsabiv, Krystexxa |
| Aurinia Pharma U.S., INC. | $406.05 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $336.86 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $324.08 | 2023-2024 | |
| Ardelyx, INC. | $258.77 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $240.68 | 2020-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $180.11 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.26 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $152.00 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.22 | 2023 | Livtencity |
| Sanofi-Aventis U.S. LLC | $121.82 | 2025 | |
| Calliditas Therapeutics US INC. | $98.40 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $92.58 | 2023-2025 | Ozempic, Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $86.52 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $69.04 | 2023-2025 | Auryxia, Vafseo |
| Alnylam Pharmaceuticals INC. | $61.21 | 2023 | Oxlumo |
| Fresenius USA Marketing, INC. | $33.50 | 2024 | Velphoro |
| Lilly USA, LLC | $24.33 | 2023 | Mounjaro |
| Opko Pharmaceuticals, LLC | $13.01 | 2023 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.